院内肺炎（HAP）治療薬のグローバル市場インサイト・予測（～2028年）

• 英文タイトル：Global Hospital-acquired Pneumonia(HAP) Drugs Market Insights and Forecast to 2028

• レポートコード：QY2203B07648
• 出版社/出版日：QYResearch / 2022年3月
• レポート形態：英文、PDF、105ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥686,000 (USD4,900)	▷ お問い合わせ
Multi User	￥1,029,000 (USD7,350)	▷ お問い合わせ
Enterprise License	￥1,372,000 (USD9,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

新型コロナウイルス感染症のパンデミックにより、世界の院内肺炎（HAP）治療薬の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に院内肺炎（HAP）治療薬の世界市場のxxx％を占める「抗菌剤」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。
中国の院内肺炎（HAP）治療薬の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの院内肺炎（HAP）治療薬市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの院内肺炎（HAP）治療薬市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。

院内肺炎（HAP）治療薬のグローバル主要メーカーには、Pfizer、GlaxoSmithKline、Merck、Mylan、Novartis、Teva Pharmaceutical Industries、AstraZeneca、Arsanis、Combioxin、Shinogi、Sun Pharmaceutical Industries、The Medicines Company、Theravance Biopharmaなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

院内肺炎（HAP）治療薬市場は、種類と用途によって区分されます。世界の院内肺炎（HAP）治療薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
抗菌剤、抗ウイルス剤、抗真菌剤

【用途別セグメント】
病院、診療所、その他

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- 院内肺炎（HAP）治療薬製品概要
- 種類別市場（抗菌剤、抗ウイルス剤、抗真菌剤）
- 用途別市場（病院、診療所、その他）
- 調査の目的
・エグゼクティブサマリー
- 世界の院内肺炎（HAP）治療薬販売量予測2017-2028
- 世界の院内肺炎（HAP）治療薬売上予測2017-2028
- 院内肺炎（HAP）治療薬の地域別販売量
- 院内肺炎（HAP）治療薬の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別院内肺炎（HAP）治療薬販売量
- 主要メーカー別院内肺炎（HAP）治療薬売上
- 主要メーカー別院内肺炎（HAP）治療薬価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模（抗菌剤、抗ウイルス剤、抗真菌剤）
- 院内肺炎（HAP）治療薬の種類別販売量
- 院内肺炎（HAP）治療薬の種類別売上
- 院内肺炎（HAP）治療薬の種類別価格
・用途別市場規模（病院、診療所、その他）
- 院内肺炎（HAP）治療薬の用途別販売量
- 院内肺炎（HAP）治療薬の用途別売上
- 院内肺炎（HAP）治療薬の用途別価格
・北米市場
- 北米の院内肺炎（HAP）治療薬市場規模（種類別、用途別）
- 主要国別の院内肺炎（HAP）治療薬市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパの院内肺炎（HAP）治療薬市場規模（種類別、用途別）
- 主要国別の院内肺炎（HAP）治療薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋の院内肺炎（HAP）治療薬市場規模（種類別、用途別）
- 主要国別の院内肺炎（HAP）治療薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米の院内肺炎（HAP）治療薬市場規模（種類別、用途別）
- 主要国別の院内肺炎（HAP）治療薬市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカの院内肺炎（HAP）治療薬市場規模（種類別、用途別）
- 主要国別の院内肺炎（HAP）治療薬市場規模（トルコ、サウジアラビア）
・企業情報
Pfizer、GlaxoSmithKline、Merck、Mylan、Novartis、Teva Pharmaceutical Industries、AstraZeneca、Arsanis、Combioxin、Shinogi、Sun Pharmaceutical Industries、The Medicines Company、Theravance Biopharma
・産業チェーン及び販売チャネル分析
- 院内肺炎（HAP）治療薬の産業チェーン分析
- 院内肺炎（HAP）治療薬の原材料
- 院内肺炎（HAP）治療薬の生産プロセス
- 院内肺炎（HAP）治療薬の販売及びマーケティング
- 院内肺炎（HAP）治療薬の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 院内肺炎（HAP）治療薬の産業動向
- 院内肺炎（HAP）治療薬のマーケットドライバー
- 院内肺炎（HAP）治療薬の課題
- 院内肺炎（HAP）治療薬の阻害要因
・主な調査結果

Market Analysis and Insights: Global Hospital-acquired Pneumonia(HAP) Drugs Market
Due to the COVID-19 pandemic, the global Hospital-acquired Pneumonia(HAP) Drugs market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Antibacterial accounting for % of the Hospital-acquired Pneumonia(HAP) Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospitals segment is altered to an % CAGR throughout this forecast period.
China Hospital-acquired Pneumonia(HAP) Drugs market size is valued at US$ million in 2021, while the US and Europe Hospital-acquired Pneumonia(HAP) Drugs are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Hospital-acquired Pneumonia(HAP) Drugs landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Hospital-acquired Pneumonia(HAP) Drugs include Pfizer, GlaxoSmithKline, Merck, Mylan, Novartis, Teva Pharmaceutical Industries, AstraZeneca, Arsanis and Combioxin, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Hospital-acquired Pneumonia(HAP) Drugs Scope and Segment
Hospital-acquired Pneumonia(HAP) Drugs market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Hospital-acquired Pneumonia(HAP) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Antibacterial
Antiviral
Antifungal
Segment by Application
Hospitals
Clinics
Other
By Company
Pfizer
GlaxoSmithKline
Merck
Mylan
Novartis
Teva Pharmaceutical Industries
AstraZeneca
Arsanis
Combioxin
Shinogi
Sun Pharmaceutical Industries
The Medicines Company
Theravance Biopharma
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

レポート目次

1 Study Coverage
1.1 Hospital-acquired Pneumonia(HAP) Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Hospital-acquired Pneumonia(HAP) Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Antibacterial
1.2.3 Antiviral
1.2.4 Antifungal
1.3 Market by Application
1.3.1 Global Hospital-acquired Pneumonia(HAP) Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Hospital-acquired Pneumonia(HAP) Drugs Sales Estimates and Forecasts 2017-2028
2.2 Global Hospital-acquired Pneumonia(HAP) Drugs Revenue Estimates and Forecasts 2017-2028
2.3 Global Hospital-acquired Pneumonia(HAP) Drugs Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Hospital-acquired Pneumonia(HAP) Drugs Sales by Region
2.4.1 Global Hospital-acquired Pneumonia(HAP) Drugs Sales by Region (2017-2022)
2.4.2 Global Sales Hospital-acquired Pneumonia(HAP) Drugs by Region (2023-2028)
2.5 Global Hospital-acquired Pneumonia(HAP) Drugs Revenue by Region
2.5.1 Global Hospital-acquired Pneumonia(HAP) Drugs Revenue by Region (2017-2022)
2.5.2 Global Hospital-acquired Pneumonia(HAP) Drugs Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Hospital-acquired Pneumonia(HAP) Drugs Sales by Manufacturers
3.1.1 Global Top Hospital-acquired Pneumonia(HAP) Drugs Manufacturers by Sales (2017-2022)
3.1.2 Global Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Hospital-acquired Pneumonia(HAP) Drugs in 2021
3.2 Global Hospital-acquired Pneumonia(HAP) Drugs Revenue by Manufacturers
3.2.1 Global Hospital-acquired Pneumonia(HAP) Drugs Revenue by Manufacturers (2017-2022)
3.2.2 Global Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Hospital-acquired Pneumonia(HAP) Drugs Revenue in 2021
3.3 Global Hospital-acquired Pneumonia(HAP) Drugs Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Hospital-acquired Pneumonia(HAP) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Hospital-acquired Pneumonia(HAP) Drugs Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Hospital-acquired Pneumonia(HAP) Drugs Sales by Type
4.1.1 Global Hospital-acquired Pneumonia(HAP) Drugs Historical Sales by Type (2017-2022)
4.1.2 Global Hospital-acquired Pneumonia(HAP) Drugs Forecasted Sales by Type (2023-2028)
4.1.3 Global Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Type (2017-2028)
4.2 Global Hospital-acquired Pneumonia(HAP) Drugs Revenue by Type
4.2.1 Global Hospital-acquired Pneumonia(HAP) Drugs Historical Revenue by Type (2017-2022)
4.2.2 Global Hospital-acquired Pneumonia(HAP) Drugs Forecasted Revenue by Type (2023-2028)
4.2.3 Global Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Type (2017-2028)
4.3 Global Hospital-acquired Pneumonia(HAP) Drugs Price by Type
4.3.1 Global Hospital-acquired Pneumonia(HAP) Drugs Price by Type (2017-2022)
4.3.2 Global Hospital-acquired Pneumonia(HAP) Drugs Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Hospital-acquired Pneumonia(HAP) Drugs Sales by Application
5.1.1 Global Hospital-acquired Pneumonia(HAP) Drugs Historical Sales by Application (2017-2022)
5.1.2 Global Hospital-acquired Pneumonia(HAP) Drugs Forecasted Sales by Application (2023-2028)
5.1.3 Global Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Application (2017-2028)
5.2 Global Hospital-acquired Pneumonia(HAP) Drugs Revenue by Application
5.2.1 Global Hospital-acquired Pneumonia(HAP) Drugs Historical Revenue by Application (2017-2022)
5.2.2 Global Hospital-acquired Pneumonia(HAP) Drugs Forecasted Revenue by Application (2023-2028)
5.2.3 Global Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Application (2017-2028)
5.3 Global Hospital-acquired Pneumonia(HAP) Drugs Price by Application
5.3.1 Global Hospital-acquired Pneumonia(HAP) Drugs Price by Application (2017-2022)
5.3.2 Global Hospital-acquired Pneumonia(HAP) Drugs Price Forecast by Application (2023-2028)
6 North America
6.1 North America Hospital-acquired Pneumonia(HAP) Drugs Market Size by Type
6.1.1 North America Hospital-acquired Pneumonia(HAP) Drugs Sales by Type (2017-2028)
6.1.2 North America Hospital-acquired Pneumonia(HAP) Drugs Revenue by Type (2017-2028)
6.2 North America Hospital-acquired Pneumonia(HAP) Drugs Market Size by Application
6.2.1 North America Hospital-acquired Pneumonia(HAP) Drugs Sales by Application (2017-2028)
6.2.2 North America Hospital-acquired Pneumonia(HAP) Drugs Revenue by Application (2017-2028)
6.3 North America Hospital-acquired Pneumonia(HAP) Drugs Market Size by Country
6.3.1 North America Hospital-acquired Pneumonia(HAP) Drugs Sales by Country (2017-2028)
6.3.2 North America Hospital-acquired Pneumonia(HAP) Drugs Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Hospital-acquired Pneumonia(HAP) Drugs Market Size by Type
7.1.1 Europe Hospital-acquired Pneumonia(HAP) Drugs Sales by Type (2017-2028)
7.1.2 Europe Hospital-acquired Pneumonia(HAP) Drugs Revenue by Type (2017-2028)
7.2 Europe Hospital-acquired Pneumonia(HAP) Drugs Market Size by Application
7.2.1 Europe Hospital-acquired Pneumonia(HAP) Drugs Sales by Application (2017-2028)
7.2.2 Europe Hospital-acquired Pneumonia(HAP) Drugs Revenue by Application (2017-2028)
7.3 Europe Hospital-acquired Pneumonia(HAP) Drugs Market Size by Country
7.3.1 Europe Hospital-acquired Pneumonia(HAP) Drugs Sales by Country (2017-2028)
7.3.2 Europe Hospital-acquired Pneumonia(HAP) Drugs Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Hospital-acquired Pneumonia(HAP) Drugs Market Size by Type
8.1.1 Asia Pacific Hospital-acquired Pneumonia(HAP) Drugs Sales by Type (2017-2028)
8.1.2 Asia Pacific Hospital-acquired Pneumonia(HAP) Drugs Revenue by Type (2017-2028)
8.2 Asia Pacific Hospital-acquired Pneumonia(HAP) Drugs Market Size by Application
8.2.1 Asia Pacific Hospital-acquired Pneumonia(HAP) Drugs Sales by Application (2017-2028)
8.2.2 Asia Pacific Hospital-acquired Pneumonia(HAP) Drugs Revenue by Application (2017-2028)
8.3 Asia Pacific Hospital-acquired Pneumonia(HAP) Drugs Market Size by Region
8.3.1 Asia Pacific Hospital-acquired Pneumonia(HAP) Drugs Sales by Region (2017-2028)
8.3.2 Asia Pacific Hospital-acquired Pneumonia(HAP) Drugs Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Hospital-acquired Pneumonia(HAP) Drugs Market Size by Type
9.1.1 Latin America Hospital-acquired Pneumonia(HAP) Drugs Sales by Type (2017-2028)
9.1.2 Latin America Hospital-acquired Pneumonia(HAP) Drugs Revenue by Type (2017-2028)
9.2 Latin America Hospital-acquired Pneumonia(HAP) Drugs Market Size by Application
9.2.1 Latin America Hospital-acquired Pneumonia(HAP) Drugs Sales by Application (2017-2028)
9.2.2 Latin America Hospital-acquired Pneumonia(HAP) Drugs Revenue by Application (2017-2028)
9.3 Latin America Hospital-acquired Pneumonia(HAP) Drugs Market Size by Country
9.3.1 Latin America Hospital-acquired Pneumonia(HAP) Drugs Sales by Country (2017-2028)
9.3.2 Latin America Hospital-acquired Pneumonia(HAP) Drugs Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Hospital-acquired Pneumonia(HAP) Drugs Market Size by Type
10.1.1 Middle East and Africa Hospital-acquired Pneumonia(HAP) Drugs Sales by Type (2017-2028)
10.1.2 Middle East and Africa Hospital-acquired Pneumonia(HAP) Drugs Revenue by Type (2017-2028)
10.2 Middle East and Africa Hospital-acquired Pneumonia(HAP) Drugs Market Size by Application
10.2.1 Middle East and Africa Hospital-acquired Pneumonia(HAP) Drugs Sales by Application (2017-2028)
10.2.2 Middle East and Africa Hospital-acquired Pneumonia(HAP) Drugs Revenue by Application (2017-2028)
10.3 Middle East and Africa Hospital-acquired Pneumonia(HAP) Drugs Market Size by Country
10.3.1 Middle East and Africa Hospital-acquired Pneumonia(HAP) Drugs Sales by Country (2017-2028)
10.3.2 Middle East and Africa Hospital-acquired Pneumonia(HAP) Drugs Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Pfizer
11.1.1 Pfizer Corporation Information
11.1.2 Pfizer Overview
11.1.3 Pfizer Hospital-acquired Pneumonia(HAP) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Pfizer Hospital-acquired Pneumonia(HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Pfizer Recent Developments
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Corporation Information
11.2.2 GlaxoSmithKline Overview
11.2.3 GlaxoSmithKline Hospital-acquired Pneumonia(HAP) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 GlaxoSmithKline Hospital-acquired Pneumonia(HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 GlaxoSmithKline Recent Developments
11.3 Merck
11.3.1 Merck Corporation Information
11.3.2 Merck Overview
11.3.3 Merck Hospital-acquired Pneumonia(HAP) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Merck Hospital-acquired Pneumonia(HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Merck Recent Developments
11.4 Mylan
11.4.1 Mylan Corporation Information
11.4.2 Mylan Overview
11.4.3 Mylan Hospital-acquired Pneumonia(HAP) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Mylan Hospital-acquired Pneumonia(HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Mylan Recent Developments
11.5 Novartis
11.5.1 Novartis Corporation Information
11.5.2 Novartis Overview
11.5.3 Novartis Hospital-acquired Pneumonia(HAP) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Novartis Hospital-acquired Pneumonia(HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Novartis Recent Developments
11.6 Teva Pharmaceutical Industries
11.6.1 Teva Pharmaceutical Industries Corporation Information
11.6.2 Teva Pharmaceutical Industries Overview
11.6.3 Teva Pharmaceutical Industries Hospital-acquired Pneumonia(HAP) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Teva Pharmaceutical Industries Hospital-acquired Pneumonia(HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Teva Pharmaceutical Industries Recent Developments
11.7 AstraZeneca
11.7.1 AstraZeneca Corporation Information
11.7.2 AstraZeneca Overview
11.7.3 AstraZeneca Hospital-acquired Pneumonia(HAP) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 AstraZeneca Hospital-acquired Pneumonia(HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 AstraZeneca Recent Developments
11.8 Arsanis
11.8.1 Arsanis Corporation Information
11.8.2 Arsanis Overview
11.8.3 Arsanis Hospital-acquired Pneumonia(HAP) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Arsanis Hospital-acquired Pneumonia(HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Arsanis Recent Developments
11.9 Combioxin
11.9.1 Combioxin Corporation Information
11.9.2 Combioxin Overview
11.9.3 Combioxin Hospital-acquired Pneumonia(HAP) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Combioxin Hospital-acquired Pneumonia(HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Combioxin Recent Developments
11.10 Shinogi
11.10.1 Shinogi Corporation Information
11.10.2 Shinogi Overview
11.10.3 Shinogi Hospital-acquired Pneumonia(HAP) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Shinogi Hospital-acquired Pneumonia(HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Shinogi Recent Developments
11.11 Sun Pharmaceutical Industries
11.11.1 Sun Pharmaceutical Industries Corporation Information
11.11.2 Sun Pharmaceutical Industries Overview
11.11.3 Sun Pharmaceutical Industries Hospital-acquired Pneumonia(HAP) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Sun Pharmaceutical Industries Hospital-acquired Pneumonia(HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Sun Pharmaceutical Industries Recent Developments
11.12 The Medicines Company
11.12.1 The Medicines Company Corporation Information
11.12.2 The Medicines Company Overview
11.12.3 The Medicines Company Hospital-acquired Pneumonia(HAP) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 The Medicines Company Hospital-acquired Pneumonia(HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 The Medicines Company Recent Developments
11.13 Theravance Biopharma
11.13.1 Theravance Biopharma Corporation Information
11.13.2 Theravance Biopharma Overview
11.13.3 Theravance Biopharma Hospital-acquired Pneumonia(HAP) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Theravance Biopharma Hospital-acquired Pneumonia(HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Theravance Biopharma Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Hospital-acquired Pneumonia(HAP) Drugs Industry Chain Analysis
12.2 Hospital-acquired Pneumonia(HAP) Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Hospital-acquired Pneumonia(HAP) Drugs Production Mode & Process
12.4 Hospital-acquired Pneumonia(HAP) Drugs Sales and Marketing
12.4.1 Hospital-acquired Pneumonia(HAP) Drugs Sales Channels
12.4.2 Hospital-acquired Pneumonia(HAP) Drugs Distributors
12.5 Hospital-acquired Pneumonia(HAP) Drugs Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Hospital-acquired Pneumonia(HAP) Drugs Industry Trends
13.2 Hospital-acquired Pneumonia(HAP) Drugs Market Drivers
13.3 Hospital-acquired Pneumonia(HAP) Drugs Market Challenges
13.4 Hospital-acquired Pneumonia(HAP) Drugs Market Restraints
14 Key Findings in The Global Hospital-acquired Pneumonia(HAP) Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Tables
Table 1. Global Hospital-acquired Pneumonia(HAP) Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Antibacterial
Table 3. Major Manufacturers of Antiviral
Table 4. Major Manufacturers of Antifungal
Table 5. Global Hospital-acquired Pneumonia(HAP) Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 7. Global Hospital-acquired Pneumonia(HAP) Drugs Sales by Region (2017-2022) & (K Pcs)
Table 8. Global Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Region (2017-2022)
Table 9. Global Hospital-acquired Pneumonia(HAP) Drugs Sales by Region (2023-2028) & (K Pcs)
Table 10. Global Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Region (2023-2028)
Table 11. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 12. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Region (2017-2022)
Table 13. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue by Region (2023-2028) & (US$ Million)
Table 14. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Region (2023-2028)
Table 15. Global Hospital-acquired Pneumonia(HAP) Drugs Sales by Manufacturers (2017-2022) & (K Pcs)
Table 16. Global Hospital-acquired Pneumonia(HAP) Drugs Sales Share by Manufacturers (2017-2022)
Table 17. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 18. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue Share by Manufacturers (2017-2022)
Table 19. Hospital-acquired Pneumonia(HAP) Drugs Price by Manufacturers (2017-2022) &(USD/Pcs)
Table 20. Global Hospital-acquired Pneumonia(HAP) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 21. Global Hospital-acquired Pneumonia(HAP) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hospital-acquired Pneumonia(HAP) Drugs as of 2021)
Table 22. Hospital-acquired Pneumonia(HAP) Drugs Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Hospital-acquired Pneumonia(HAP) Drugs Product Offered
Table 24. Date of Manufacturers Enter into Hospital-acquired Pneumonia(HAP) Drugs Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Hospital-acquired Pneumonia(HAP) Drugs Sales by Type (2017-2022) & (K Pcs)
Table 27. Global Hospital-acquired Pneumonia(HAP) Drugs Sales by Type (2023-2028) & (K Pcs)
Table 28. Global Hospital-acquired Pneumonia(HAP) Drugs Sales Share by Type (2017-2022)
Table 29. Global Hospital-acquired Pneumonia(HAP) Drugs Sales Share by Type (2023-2028)
Table 30. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 31. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 32. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue Share by Type (2017-2022)
Table 33. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue Share by Type (2023-2028)
Table 34. Hospital-acquired Pneumonia(HAP) Drugs Price by Type (2017-2022) & (USD/Pcs)
Table 35. Global Hospital-acquired Pneumonia(HAP) Drugs Price Forecast by Type (2023-2028) & (USD/Pcs)
Table 36. Global Hospital-acquired Pneumonia(HAP) Drugs Sales by Application (2017-2022) & (K Pcs)
Table 37. Global Hospital-acquired Pneumonia(HAP) Drugs Sales by Application (2023-2028) & (K Pcs)
Table 38. Global Hospital-acquired Pneumonia(HAP) Drugs Sales Share by Application (2017-2022)
Table 39. Global Hospital-acquired Pneumonia(HAP) Drugs Sales Share by Application (2023-2028)
Table 40. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 41. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 42. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue Share by Application (2017-2022)
Table 43. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue Share by Application (2023-2028)
Table 44. Hospital-acquired Pneumonia(HAP) Drugs Price by Application (2017-2022) & (USD/Pcs)
Table 45. Global Hospital-acquired Pneumonia(HAP) Drugs Price Forecast by Application (2023-2028) & (USD/Pcs)
Table 46. North America Hospital-acquired Pneumonia(HAP) Drugs Sales by Type (2017-2022) & (K Pcs)
Table 47. North America Hospital-acquired Pneumonia(HAP) Drugs Sales by Type (2023-2028) & (K Pcs)
Table 48. North America Hospital-acquired Pneumonia(HAP) Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 49. North America Hospital-acquired Pneumonia(HAP) Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 50. North America Hospital-acquired Pneumonia(HAP) Drugs Sales by Application (2017-2022) & (K Pcs)
Table 51. North America Hospital-acquired Pneumonia(HAP) Drugs Sales by Application (2023-2028) & (K Pcs)
Table 52. North America Hospital-acquired Pneumonia(HAP) Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 53. North America Hospital-acquired Pneumonia(HAP) Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 54. North America Hospital-acquired Pneumonia(HAP) Drugs Sales by Country (2017-2022) & (K Pcs)
Table 55. North America Hospital-acquired Pneumonia(HAP) Drugs Sales by Country (2023-2028) & (K Pcs)
Table 56. North America Hospital-acquired Pneumonia(HAP) Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 57. North America Hospital-acquired Pneumonia(HAP) Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 58. Europe Hospital-acquired Pneumonia(HAP) Drugs Sales by Type (2017-2022) & (K Pcs)
Table 59. Europe Hospital-acquired Pneumonia(HAP) Drugs Sales by Type (2023-2028) & (K Pcs)
Table 60. Europe Hospital-acquired Pneumonia(HAP) Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 61. Europe Hospital-acquired Pneumonia(HAP) Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 62. Europe Hospital-acquired Pneumonia(HAP) Drugs Sales by Application (2017-2022) & (K Pcs)
Table 63. Europe Hospital-acquired Pneumonia(HAP) Drugs Sales by Application (2023-2028) & (K Pcs)
Table 64. Europe Hospital-acquired Pneumonia(HAP) Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 65. Europe Hospital-acquired Pneumonia(HAP) Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 66. Europe Hospital-acquired Pneumonia(HAP) Drugs Sales by Country (2017-2022) & (K Pcs)
Table 67. Europe Hospital-acquired Pneumonia(HAP) Drugs Sales by Country (2023-2028) & (K Pcs)
Table 68. Europe Hospital-acquired Pneumonia(HAP) Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 69. Europe Hospital-acquired Pneumonia(HAP) Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 70. Asia Pacific Hospital-acquired Pneumonia(HAP) Drugs Sales by Type (2017-2022) & (K Pcs)
Table 71. Asia Pacific Hospital-acquired Pneumonia(HAP) Drugs Sales by Type (2023-2028) & (K Pcs)
Table 72. Asia Pacific Hospital-acquired Pneumonia(HAP) Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 73. Asia Pacific Hospital-acquired Pneumonia(HAP) Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 74. Asia Pacific Hospital-acquired Pneumonia(HAP) Drugs Sales by Application (2017-2022) & (K Pcs)
Table 75. Asia Pacific Hospital-acquired Pneumonia(HAP) Drugs Sales by Application (2023-2028) & (K Pcs)
Table 76. Asia Pacific Hospital-acquired Pneumonia(HAP) Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 77. Asia Pacific Hospital-acquired Pneumonia(HAP) Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 78. Asia Pacific Hospital-acquired Pneumonia(HAP) Drugs Sales by Region (2017-2022) & (K Pcs)
Table 79. Asia Pacific Hospital-acquired Pneumonia(HAP) Drugs Sales by Region (2023-2028) & (K Pcs)
Table 80. Asia Pacific Hospital-acquired Pneumonia(HAP) Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 81. Asia Pacific Hospital-acquired Pneumonia(HAP) Drugs Revenue by Region (2023-2028) & (US$ Million)
Table 82. Latin America Hospital-acquired Pneumonia(HAP) Drugs Sales by Type (2017-2022) & (K Pcs)
Table 83. Latin America Hospital-acquired Pneumonia(HAP) Drugs Sales by Type (2023-2028) & (K Pcs)
Table 84. Latin America Hospital-acquired Pneumonia(HAP) Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 85. Latin America Hospital-acquired Pneumonia(HAP) Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 86. Latin America Hospital-acquired Pneumonia(HAP) Drugs Sales by Application (2017-2022) & (K Pcs)
Table 87. Latin America Hospital-acquired Pneumonia(HAP) Drugs Sales by Application (2023-2028) & (K Pcs)
Table 88. Latin America Hospital-acquired Pneumonia(HAP) Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 89. Latin America Hospital-acquired Pneumonia(HAP) Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 90. Latin America Hospital-acquired Pneumonia(HAP) Drugs Sales by Country (2017-2022) & (K Pcs)
Table 91. Latin America Hospital-acquired Pneumonia(HAP) Drugs Sales by Country (2023-2028) & (K Pcs)
Table 92. Latin America Hospital-acquired Pneumonia(HAP) Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 93. Latin America Hospital-acquired Pneumonia(HAP) Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 94. Middle East and Africa Hospital-acquired Pneumonia(HAP) Drugs Sales by Type (2017-2022) & (K Pcs)
Table 95. Middle East and Africa Hospital-acquired Pneumonia(HAP) Drugs Sales by Type (2023-2028) & (K Pcs)
Table 96. Middle East and Africa Hospital-acquired Pneumonia(HAP) Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 97. Middle East and Africa Hospital-acquired Pneumonia(HAP) Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 98. Middle East and Africa Hospital-acquired Pneumonia(HAP) Drugs Sales by Application (2017-2022) & (K Pcs)
Table 99. Middle East and Africa Hospital-acquired Pneumonia(HAP) Drugs Sales by Application (2023-2028) & (K Pcs)
Table 100. Middle East and Africa Hospital-acquired Pneumonia(HAP) Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 101. Middle East and Africa Hospital-acquired Pneumonia(HAP) Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 102. Middle East and Africa Hospital-acquired Pneumonia(HAP) Drugs Sales by Country (2017-2022) & (K Pcs)
Table 103. Middle East and Africa Hospital-acquired Pneumonia(HAP) Drugs Sales by Country (2023-2028) & (K Pcs)
Table 104. Middle East and Africa Hospital-acquired Pneumonia(HAP) Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 105. Middle East and Africa Hospital-acquired Pneumonia(HAP) Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 106. Pfizer Corporation Information
Table 107. Pfizer Description and Major Businesses
Table 108. Pfizer Hospital-acquired Pneumonia(HAP) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 109. Pfizer Hospital-acquired Pneumonia(HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 110. Pfizer Recent Developments
Table 111. GlaxoSmithKline Corporation Information
Table 112. GlaxoSmithKline Description and Major Businesses
Table 113. GlaxoSmithKline Hospital-acquired Pneumonia(HAP) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 114. GlaxoSmithKline Hospital-acquired Pneumonia(HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 115. GlaxoSmithKline Recent Developments
Table 116. Merck Corporation Information
Table 117. Merck Description and Major Businesses
Table 118. Merck Hospital-acquired Pneumonia(HAP) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 119. Merck Hospital-acquired Pneumonia(HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 120. Merck Recent Developments
Table 121. Mylan Corporation Information
Table 122. Mylan Description and Major Businesses
Table 123. Mylan Hospital-acquired Pneumonia(HAP) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 124. Mylan Hospital-acquired Pneumonia(HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 125. Mylan Recent Developments
Table 126. Novartis Corporation Information
Table 127. Novartis Description and Major Businesses
Table 128. Novartis Hospital-acquired Pneumonia(HAP) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 129. Novartis Hospital-acquired Pneumonia(HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 130. Novartis Recent Developments
Table 131. Teva Pharmaceutical Industries Corporation Information
Table 132. Teva Pharmaceutical Industries Description and Major Businesses
Table 133. Teva Pharmaceutical Industries Hospital-acquired Pneumonia(HAP) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 134. Teva Pharmaceutical Industries Hospital-acquired Pneumonia(HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 135. Teva Pharmaceutical Industries Recent Developments
Table 136. AstraZeneca Corporation Information
Table 137. AstraZeneca Description and Major Businesses
Table 138. AstraZeneca Hospital-acquired Pneumonia(HAP) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 139. AstraZeneca Hospital-acquired Pneumonia(HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 140. AstraZeneca Recent Developments
Table 141. Arsanis Corporation Information
Table 142. Arsanis Description and Major Businesses
Table 143. Arsanis Hospital-acquired Pneumonia(HAP) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 144. Arsanis Hospital-acquired Pneumonia(HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 145. Arsanis Recent Developments
Table 146. Combioxin Corporation Information
Table 147. Combioxin Description and Major Businesses
Table 148. Combioxin Hospital-acquired Pneumonia(HAP) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 149. Combioxin Hospital-acquired Pneumonia(HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 150. Combioxin Recent Developments
Table 151. Shinogi Corporation Information
Table 152. Shinogi Description and Major Businesses
Table 153. Shinogi Hospital-acquired Pneumonia(HAP) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 154. Shinogi Hospital-acquired Pneumonia(HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 155. Shinogi Recent Developments
Table 156. Sun Pharmaceutical Industries Corporation Information
Table 157. Sun Pharmaceutical Industries Description and Major Businesses
Table 158. Sun Pharmaceutical Industries Hospital-acquired Pneumonia(HAP) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 159. Sun Pharmaceutical Industries Hospital-acquired Pneumonia(HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 160. Sun Pharmaceutical Industries Recent Developments
Table 161. The Medicines Company Corporation Information
Table 162. The Medicines Company Description and Major Businesses
Table 163. The Medicines Company Hospital-acquired Pneumonia(HAP) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 164. The Medicines Company Hospital-acquired Pneumonia(HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 165. The Medicines Company Recent Developments
Table 166. Theravance Biopharma Corporation Information
Table 167. Theravance Biopharma Description and Major Businesses
Table 168. Theravance Biopharma Hospital-acquired Pneumonia(HAP) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 169. Theravance Biopharma Hospital-acquired Pneumonia(HAP) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 170. Theravance Biopharma Recent Developments
Table 171. Key Raw Materials Lists
Table 172. Raw Materials Key Suppliers Lists
Table 173. Hospital-acquired Pneumonia(HAP) Drugs Distributors List
Table 174. Hospital-acquired Pneumonia(HAP) Drugs Customers List
Table 175. Hospital-acquired Pneumonia(HAP) Drugs Market Trends
Table 176. Hospital-acquired Pneumonia(HAP) Drugs Market Drivers
Table 177. Hospital-acquired Pneumonia(HAP) Drugs Market Challenges
Table 178. Hospital-acquired Pneumonia(HAP) Drugs Market Restraints
Table 179. Research Programs/Design for This Report
Table 180. Key Data Information from Secondary Sources
Table 181. Key Data Information from Primary Sources
List of Figures
Figure 1. Hospital-acquired Pneumonia(HAP) Drugs Product Picture
Figure 3. Global Hospital-acquired Pneumonia(HAP) Drugs Market Share by Type in 2021 & 2028
Figure 3. Antibacterial Product Picture
Figure 4. Antiviral Product Picture
Figure 5. Antifungal Product Picture
Figure 6. Global Hospital-acquired Pneumonia(HAP) Drugs Market Share by Application in 2021 & 2028
Figure 7. Hospitals
Figure 8. Clinics
Figure 9. Other
Figure 10. Hospital-acquired Pneumonia(HAP) Drugs Report Years Considered
Figure 11. Global Hospital-acquired Pneumonia(HAP) Drugs Sales 2017-2028 (K Pcs)
Figure 12. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue 2017-2028 (US$ Million)
Figure 14. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 15. Global Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Region (2017-2022)
Figure 16. Global Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Region (2023-2028)
Figure 17. North America Hospital-acquired Pneumonia(HAP) Drugs Sales YoY (2017-2028) & (K Pcs)
Figure 18. North America Hospital-acquired Pneumonia(HAP) Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 19. Europe Hospital-acquired Pneumonia(HAP) Drugs Sales YoY (2017-2028) & (K Pcs)
Figure 20. Europe Hospital-acquired Pneumonia(HAP) Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 21. Asia-Pacific Hospital-acquired Pneumonia(HAP) Drugs Sales YoY (2017-2028) & (K Pcs)
Figure 22. Asia-Pacific Hospital-acquired Pneumonia(HAP) Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 23. Latin America Hospital-acquired Pneumonia(HAP) Drugs Sales YoY (2017-2028) & (K Pcs)
Figure 24. Latin America Hospital-acquired Pneumonia(HAP) Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 25. Middle East & Africa Hospital-acquired Pneumonia(HAP) Drugs Sales YoY (2017-2028) & (K Pcs)
Figure 26. Middle East & Africa Hospital-acquired Pneumonia(HAP) Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 27. The Hospital-acquired Pneumonia(HAP) Drugs Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 28. The Top 5 and 10 Largest Manufacturers of Hospital-acquired Pneumonia(HAP) Drugs in the World: Market Share by Hospital-acquired Pneumonia(HAP) Drugs Revenue in 2021
Figure 29. Global Hospital-acquired Pneumonia(HAP) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 30. Global Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Type (2017-2028)
Figure 31. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Type (2017-2028)
Figure 32. Global Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Application (2017-2028)
Figure 33. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Application (2017-2028)
Figure 34. North America Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Type (2017-2028)
Figure 35. North America Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Type (2017-2028)
Figure 36. North America Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Application (2017-2028)
Figure 37. North America Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Application (2017-2028)
Figure 38. North America Hospital-acquired Pneumonia(HAP) Drugs Sales Share by Country (2017-2028)
Figure 39. North America Hospital-acquired Pneumonia(HAP) Drugs Revenue Share by Country (2017-2028)
Figure 40. U.S. Hospital-acquired Pneumonia(HAP) Drugs Revenue (2017-2028) & (US$ Million)
Figure 41. Canada Hospital-acquired Pneumonia(HAP) Drugs Revenue (2017-2028) & (US$ Million)
Figure 42. Europe Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Type (2017-2028)
Figure 43. Europe Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Type (2017-2028)
Figure 44. Europe Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Application (2017-2028)
Figure 45. Europe Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Application (2017-2028)
Figure 46. Europe Hospital-acquired Pneumonia(HAP) Drugs Sales Share by Country (2017-2028)
Figure 47. Europe Hospital-acquired Pneumonia(HAP) Drugs Revenue Share by Country (2017-2028)
Figure 48. Germany Hospital-acquired Pneumonia(HAP) Drugs Revenue (2017-2028) & (US$ Million)
Figure 49. France Hospital-acquired Pneumonia(HAP) Drugs Revenue (2017-2028) & (US$ Million)
Figure 50. U.K. Hospital-acquired Pneumonia(HAP) Drugs Revenue (2017-2028) & (US$ Million)
Figure 51. Italy Hospital-acquired Pneumonia(HAP) Drugs Revenue (2017-2028) & (US$ Million)
Figure 52. Russia Hospital-acquired Pneumonia(HAP) Drugs Revenue (2017-2028) & (US$ Million)
Figure 53. Asia Pacific Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Type (2017-2028)
Figure 54. Asia Pacific Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Type (2017-2028)
Figure 55. Asia Pacific Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Application (2017-2028)
Figure 56. Asia Pacific Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Application (2017-2028)
Figure 57. Asia Pacific Hospital-acquired Pneumonia(HAP) Drugs Sales Share by Region (2017-2028)
Figure 58. Asia Pacific Hospital-acquired Pneumonia(HAP) Drugs Revenue Share by Region (2017-2028)
Figure 59. China Hospital-acquired Pneumonia(HAP) Drugs Revenue (2017-2028) & (US$ Million)
Figure 60. Japan Hospital-acquired Pneumonia(HAP) Drugs Revenue (2017-2028) & (US$ Million)
Figure 61. South Korea Hospital-acquired Pneumonia(HAP) Drugs Revenue (2017-2028) & (US$ Million)
Figure 62. India Hospital-acquired Pneumonia(HAP) Drugs Revenue (2017-2028) & (US$ Million)
Figure 63. Australia Hospital-acquired Pneumonia(HAP) Drugs Revenue (2017-2028) & (US$ Million)
Figure 64. China Taiwan Hospital-acquired Pneumonia(HAP) Drugs Revenue (2017-2028) & (US$ Million)
Figure 65. Indonesia Hospital-acquired Pneumonia(HAP) Drugs Revenue (2017-2028) & (US$ Million)
Figure 66. Thailand Hospital-acquired Pneumonia(HAP) Drugs Revenue (2017-2028) & (US$ Million)
Figure 67. Malaysia Hospital-acquired Pneumonia(HAP) Drugs Revenue (2017-2028) & (US$ Million)
Figure 68. Latin America Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Type (2017-2028)
Figure 69. Latin America Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Type (2017-2028)
Figure 70. Latin America Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Application (2017-2028)
Figure 71. Latin America Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Application (2017-2028)
Figure 72. Latin America Hospital-acquired Pneumonia(HAP) Drugs Sales Share by Country (2017-2028)
Figure 73. Latin America Hospital-acquired Pneumonia(HAP) Drugs Revenue Share by Country (2017-2028)
Figure 74. Mexico Hospital-acquired Pneumonia(HAP) Drugs Revenue (2017-2028) & (US$ Million)
Figure 75. Brazil Hospital-acquired Pneumonia(HAP) Drugs Revenue (2017-2028) & (US$ Million)
Figure 76. Argentina Hospital-acquired Pneumonia(HAP) Drugs Revenue (2017-2028) & (US$ Million)
Figure 77. Middle East and Africa Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Type (2017-2028)
Figure 78. Middle East and Africa Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Type (2017-2028)
Figure 79. Middle East and Africa Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Application (2017-2028)
Figure 80. Middle East and Africa Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Application (2017-2028)
Figure 81. Middle East and Africa Hospital-acquired Pneumonia(HAP) Drugs Sales Share by Country (2017-2028)
Figure 82. Middle East and Africa Hospital-acquired Pneumonia(HAP) Drugs Revenue Share by Country (2017-2028)
Figure 83. Turkey Hospital-acquired Pneumonia(HAP) Drugs Revenue (2017-2028) & (US$ Million)
Figure 84. Saudi Arabia Hospital-acquired Pneumonia(HAP) Drugs Revenue (2017-2028) & (US$ Million)
Figure 85. UAE Hospital-acquired Pneumonia(HAP) Drugs Revenue (2017-2028) & (US$ Million)
Figure 86. Hospital-acquired Pneumonia(HAP) Drugs Value Chain
Figure 87. Hospital-acquired Pneumonia(HAP) Drugs Production Process
Figure 88. Channels of Distribution
Figure 89. Distributors Profiles
Figure 90. Bottom-up and Top-down Approaches for This Report
Figure 91. Data Triangulation
Figure 92. Key Executives Interviewed

以下、関連資料のご紹介

疼痛治療薬のグローバル市場インサイト・予測（～2028年）

Global Drugs for Pain Management Market Insights and Forecast to 2028
QY2203B14333 2022年3月 113Pages
新型コロナウイルス感染症のパンデミックにより、世界の疼痛治療薬の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に疼痛治療薬の世界市場のxx...

1,3-プロパンジオール (PDO)のグローバル市場インサイト・予測（～2028年）

Global 1,3-Propanediol(PDO) Market Insights and Forecast to 2028
QY2203B00031 2022年3月 73Pages
新型コロナウイルス感染症のパンデミックにより、世界の1,3-プロパンジオール (PDO)の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に...

アクリル酸2-プロピルヘプチル(2-PHA)のグローバル市場インサイト・予測（～2028年）

Global 2-Propylheptyl Acrylate (2-PHA) Market Insights, Forecast to 2028
QY2203B01339 2022年3月 75Pages
新型コロナウイルス感染症のパンデミックにより、世界のアクリル酸2-プロピルヘプチル(2-PHA)の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、20...

ジブチルアミン(DBA)のグローバル市場インサイト・予測（～2028年）

Global Dibutylamine(DBA)(CAS 111-92-2) Market Insights and Forecast to 2028
QY2203B03170 2022年3月 92Pages
新型コロナウイルス感染症のパンデミックにより、世界のジブチルアミン(DBA)の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にジブチルアミ...

GaNウェーハ用CMPパッド（GaN基板）のグローバル市場インサイト・予測（～2028年）

Global CMP Pads for GaN Wafer (GaN Substrate) Market Insights, Forecast to 2028
QY2203B00612 2022年3月 73Pages
新型コロナウイルス感染症のパンデミックにより、世界のGaNウェーハ用CMPパッド（GaN基板）の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、202...

埋立ガス(LFG)のグローバル市場インサイト・予測（～2028年）

Global Landfill Gas (LFG) Market Insights and Forecast to 2028
QY2203B13853 2022年3月 113Pages
新型コロナウイルス感染症のパンデミックにより、世界の埋立ガス(LFG)の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に埋立ガス(LFG)...

VHFデータ交換システム（VDES）のグローバル市場インサイト・予測（～2028年）

Global VHF Data Exchange System Market Insights and Forecast to 2028
QY2203B01213 2022年3月 109Pages
新型コロナウイルス感染症のパンデミックにより、世界のVHFデータ交換システム（VDES）の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に...

ポリアミド12 (PA 12 & ナイロン12)のグローバル市場インサイト・予測（～2028年）

Global Polyamide 12 (PA 12 & Nylon 12) Market Insights and Forecast to 2028
QY2203B06212 2022年3月 77Pages
新型コロナウイルス感染症のパンデミックにより、世界のポリアミド12 (PA 12 & ナイロン12)の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、...

ニコチンアミドアデニンジヌクレオチド（NAD）のグローバル市場インサイト・予測（～2028年）

Pages
...

電子用プロピレン(C3H6)のグローバル市場インサイト・予測（～2028年）

Global Electronic Grade Propylene (C3H6) Market Insights, Forecast to 2028
QY2203B12650 2022年3月 78Pages
新型コロナウイルス感染症のパンデミックにより、世界の電子用プロピレン(C3H6)の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に電子用プ...

疼痛治療薬のグローバル市場インサイト・予測（～2028年） Pain is complex, so there are many treatment options -- medications, therapies, and mind-body techniques. Market Analysis and Insights: Global Drugs for Pain Management Market The global Drugs for Pain Management market size is projected to reach US$ million by 2028, from US$ million in 2021, at a C…
皮膚剥離症治療薬のグローバル市場インサイト・予測（～2028年） Cutaneous Fribrosis Treatment refers to the treatment of skin myelofibrosis by drugs such as corticosteroids, anti-fibrotic drugs, and immunotherapy drugs. Market Analysis and Insights: Global Cutaneous Fribrosis Treatment Market Due to the COVID-19 pandemic, the global Cutaneous Fribrosis Treatment…
閉鎖式危険薬物移送デバイスのグローバル市場 2021年：企業別、地域別、種類・用途別 The Hazardous Drugs Closed System Transfer Device market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optim…
注射用デヒドロアンドログラポライドコハク酸カリウムのグローバル市場インサイト・予測（～2028年） Market Analysis and Insights: Global Potassium Dehydroandrograpolide Succinate for Injection Market Due to the COVID-19 pandemic, the global Potassium Dehydroandrograpolide Succinate for Injection market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ mi…
過活動膀胱（OAB）治療のグローバル市場インサイト・予測（～2028年） Overactive bladder (OAB) is a bladder disorder that results in an abnormal urge to urinate, urinary frequency, and nocturia (voiding at night). Some patients may also experience urinary incontinence (involuntary loss of bladder control). This report only focuses on the treatment drugs and Device. Ma…